In a multicenter , double-blind randomized controlled trial in progress at three intensive care units across Denmark , we randomly assign eligible critically ill adults with acute kidney injury into a treatment ( 1 mg/kg enoxaparin subcutaneously once daily ) or control arm ( 40 mg enoxaparin subcutaneously once daily ) upon commencement of continuous renal replacement therapy.We calculated that with 133 patients in each group , the study would have 80 % power to show a 40 % reduction in the relative risk of venous thromboembolism with 1 mg/kg enoxaparin , at a two-sided alpha level of 0.05 .